[go: up one dir, main page]

BR9909961A - Derivados de cadeia lateral alquila e alquenila funcionalizados de glicinamidas como inibidores de farnesil transferase - Google Patents

Derivados de cadeia lateral alquila e alquenila funcionalizados de glicinamidas como inibidores de farnesil transferase

Info

Publication number
BR9909961A
BR9909961A BR9909961-6A BR9909961A BR9909961A BR 9909961 A BR9909961 A BR 9909961A BR 9909961 A BR9909961 A BR 9909961A BR 9909961 A BR9909961 A BR 9909961A
Authority
BR
Brazil
Prior art keywords
glycinamides
alkyl
transferase inhibitors
farnesyl transferase
functionalized derivatives
Prior art date
Application number
BR9909961-6A
Other languages
English (en)
Inventor
Annette Marian Doherty
James Stanley Kaltenbronn
Daniele Marie Leonard
Dennis Joseph Mcnamara
John Quin Iii
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR9909961A publication Critical patent/BR9909961A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE CADEIA LATERAL ALQUILA E ALQUENILA FUNCIONALIZADOS DE GLICINAMIDAS COMO INIBIDORES DE FARNESIL TRANSFERASE". A presente invenção propicia compostos de fórmula (I). A presente invenção providencia também um método para o tratamento do câncer e tratamento ou prevenção da restenose ou aterosclerose. Também providencia-se, por meio da presenta invenção, uma composição farmaceuticamente aceitável contendo um composto de Fórmula I.
BR9909961-6A 1998-04-27 1999-03-19 Derivados de cadeia lateral alquila e alquenila funcionalizados de glicinamidas como inibidores de farnesil transferase BR9909961A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8325598P 1998-04-27 1998-04-27
PCT/US1999/006090 WO1999055725A1 (en) 1998-04-27 1999-03-19 Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors

Publications (1)

Publication Number Publication Date
BR9909961A true BR9909961A (pt) 2000-12-26

Family

ID=22177160

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909961-6A BR9909961A (pt) 1998-04-27 1999-03-19 Derivados de cadeia lateral alquila e alquenila funcionalizados de glicinamidas como inibidores de farnesil transferase

Country Status (15)

Country Link
US (1) US6369034B1 (pt)
EP (1) EP1076663B1 (pt)
JP (1) JP2002513031A (pt)
KR (1) KR20010043035A (pt)
AT (1) ATE259826T1 (pt)
AU (1) AU759492B2 (pt)
BR (1) BR9909961A (pt)
CA (1) CA2322944C (pt)
DE (1) DE69914893T2 (pt)
DK (1) DK1076663T3 (pt)
ES (1) ES2214021T3 (pt)
NZ (1) NZ507165A (pt)
PT (1) PT1076663E (pt)
WO (1) WO1999055725A1 (pt)
ZA (1) ZA200006035B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034239A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6284755B1 (en) 1998-12-08 2001-09-04 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP1539234A4 (en) * 2002-09-05 2006-02-15 Medimmune Inc METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
JP3837633B2 (ja) * 2002-11-19 2006-10-25 株式会社クレディアジャパン 新規な機能性ペプチド核酸およびその製法
EP2316487B1 (en) 2003-04-11 2014-06-11 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
DE10326303A1 (de) * 2003-06-11 2004-12-30 Celares Gmbh Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung
CA2536238C (en) 2003-08-18 2015-04-07 Medimmune, Inc. Humanization of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
AU2006254936A1 (en) * 2005-06-07 2006-12-14 The Trustees Of The University Of Pennesylvania Inhibitors of the alpha2beta1/GPIa-IIa integrin
US8987306B2 (en) * 2005-06-07 2015-03-24 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
JP2008546805A (ja) 2005-06-23 2008-12-25 メディミューン，エルエルシー 最適な凝集および断片化プロフィールを有する抗体製剤
WO2007027742A2 (en) * 2005-08-31 2007-03-08 The Trustees Of The University Of Pennsylvania SMALL MOLECULE INTEGRIN α2βl/GPIa-IIa ANTAGONISTS
NZ596091A (en) 2006-08-28 2012-07-27 Jolla Inst Allergy Immunolog Antagonistic human light-specific human monoclonal antibodies
WO2008121615A2 (en) 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation
BRPI0818810A2 (pt) 2007-10-31 2014-10-29 Medimmune Llc Esqueletos d polipeptídeo recombinante e multimérico, molécula de ácido n ucleico isolado, vetor de expressão, célula hospedeira, biblioteca de exibição de polipeptídeo, coleção de moléculas de ácido nucleico isolado, métodos para obter um esqueleto de polipeptídeo e pelo menos dois esqueletos, para detectar um composto em uma amostra, para capturar um composto em uma amostra, para prevenir, tratar, controlar ou melhorar uma doença, para diagnose ou formação de imagem de uma doença para purificar e produzir um esqueleto, para ensaiar ou detectar a ligação de um esqueleto a um alvo, para usar o esqueleto e para prevenir, tratar, melhora ou controlar câncer, composição estéril, isenta de pirógeno, composição farmacêutica, e, processo escalável.
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
SG11201502757QA (en) 2012-10-09 2015-05-28 Igenica Biotherapeutics Inc Anti-c16orf54 antibodies and methods of use thereof
EP3003390B1 (en) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
KR20160054501A (ko) 2013-08-26 2016-05-16 맵백스 테라퓨틱스, 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
HUE055189T2 (hu) 2014-06-04 2021-11-29 Biontech Res And Development Inc Humán monoklonális antitestek a GD2 ganglioziddal ellen
DK3333191T3 (da) 2014-12-11 2020-10-26 Pf Medicament Anti-C10ORF54-antistoffer og anvendelser deraf
RU2725221C2 (ru) 2015-03-03 2020-06-30 Кимаб Лимитед Антитела, их применение и способы применения
KR102815803B1 (ko) 2015-12-02 2025-06-05 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
MX2018006613A (es) 2015-12-02 2019-01-30 Stcube & Co Inc Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN111148762A (zh) 2017-05-31 2020-05-12 斯特库伯株式会社 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
JP7768666B2 (ja) 2017-05-31 2025-11-12 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
WO2018226671A1 (en) 2017-06-06 2018-12-13 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
JP7256796B2 (ja) 2017-10-13 2023-04-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体
US20230243836A1 (en) 2018-07-20 2023-08-03 Pierre Fabre Medicament Receptor for vista
US20230271917A1 (en) * 2020-07-22 2023-08-31 Fog Pharmaceuticals, Inc. Amino acids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU678625B2 (en) * 1993-09-30 1997-06-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU681454B2 (en) 1993-11-05 1997-08-28 Warner-Lambert Company Substituted DI- and tripeptide inhibitors of protein:farnesyl transferase
US5571792A (en) * 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
NZ332712A (en) 1996-05-22 2000-07-28 Warner Lambert Co Polypeptide inhibitors of protein farnesyl transferase
WO1998027109A1 (en) * 1996-12-17 1998-06-25 Warner-Lambert Company Cycloalkyl inhibitors of protein farnesyltransferase
AU6877998A (en) * 1997-04-11 1998-11-11 Warner-Lambert Company Dipeptide inhibitors of protein farnesyltransferase

Also Published As

Publication number Publication date
ZA200006035B (en) 2002-01-28
DE69914893T2 (de) 2004-07-22
AU759492B2 (en) 2003-04-17
CA2322944A1 (en) 1999-11-04
EP1076663B1 (en) 2004-02-18
EP1076663A1 (en) 2001-02-21
WO1999055725A1 (en) 1999-11-04
AU3358799A (en) 1999-11-16
PT1076663E (pt) 2004-06-30
JP2002513031A (ja) 2002-05-08
DK1076663T3 (da) 2004-06-01
ATE259826T1 (de) 2004-03-15
NZ507165A (en) 2003-06-30
KR20010043035A (ko) 2001-05-25
ES2214021T3 (es) 2004-09-01
DE69914893D1 (de) 2004-03-25
CA2322944C (en) 2003-05-20
US6369034B1 (en) 2002-04-09

Similar Documents

Publication Publication Date Title
BR9909961A (pt) Derivados de cadeia lateral alquila e alquenila funcionalizados de glicinamidas como inibidores de farnesil transferase
ATE307119T1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
DE69432614D1 (de) Alkohol und Aldehyde Derivate als Cathepsin L Inhibitore und als Inhibitore der Knochenresorption
ES2097653T3 (es) Nuevos derivados de desoxigalactonojirimicina.
ATE192649T1 (de) Stereochemische wortmanninderivate
ES2130930A1 (es) Recubrimientos y materiales de registro estabilizados con absorbentes de ultravioleta de benzotriazol.
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
AU681021B2 (en) Indole derivative and medicine containing the same
DK1163258T3 (da) Derivater af 22R-hydroxycholesta-8, 14-dien til inhiberingen af meiosis
ATE265854T1 (de) Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
ES2059685T3 (es) Acilaminoalquilpiridinamidas inhibidoras de metastasis tumoral.
NO20004477L (no) Anvendelse av organiske karbonater for vasking av metalloverflater
EA199800931A1 (ru) Способ получения ингибиторов фосфодиэстеразы iv
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
MY117662A (en) Organic compounds
NZ300640A (en) Glycylanilide derivatives useful in treating hypercholesterolemia or atherosclerosis by inhibiting LDL oxidation.
AP2001002047A0 (en) Isoquinoliness as urokinase inhibitors.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1975 DE 11/11/2008.